InvestorsHub Logo
Followers 17
Posts 3778
Boards Moderated 0
Alias Born 02/21/2009

Re: None

Friday, 07/08/2022 10:28:06 AM

Friday, July 08, 2022 10:28:06 AM

Post# of 64350
Here is what's coming from Deitsch and NPHC

Multiple Sclerosis Trials

Government Grants for validation of NPHC Nerve Agent Countermeasure

Adding to NPHC's 21 Patents

Additional Social Media Endorsements

New Products from NPHC


Here is what Deitsch the CEO has done for NPHC in 19 years:


Pink Current Status

Added Many patents and trademarks to Nutra's portfolio

Clinical Trials in Multiple Phases

1. Multiple Sclerosis Trials

2. Herpes Simplex Infections 1 & 2 Trials

3. Adrenomyeloneuropathy Trials

4. HIV Trials

5. Amyotrophic Lateral Sclerosis Trials

6. Rheumatoid Arthritis Trials

7. Pain Trials

Products launched and brought to Market

1. Cobroxin

2. Nyloxin

3. Pet Pain Away

4. Equine pain Away

5. Luxury Feet

Published Research

http://receptopharm.com/drug_development/published_research.php
https://www.nutrapharma.com/research

Increased Sales on Amazon and Walmart

RPI-78M has received Orphan Drug Designation from the FDA for the treatment of Pediatric Multiple Sclerosis

Huge personal loans from Deitsch to NPHC tells me the CEO knows and believes in NPHC

Nyloxin, I put that Sh*t on everything!!!